Who we are
Expanded Access is now Uniphar
Expanded and Global Access
An Expanded Access Program, or EAP, gives patients with high unmet medical needs access to therapies that are not yet commercially available including innovative therapies such as advanced therapies. Such programs are also known as named patient, post-trial access, early access, managed access or compassionate use programs depending on the regulatory framework in different regions.
Often, patients with serious or life-threatening conditions, for which there are no other suitable treatments, are not eligible or able to participate in the clinical study for investigational drugs being developed for their condition.
Uniphar enables pharma and biotech companies to offer patients access to life changing therapies via Global Access Programs. Uniphar have experience in investigational and unlicensed medicines to advanced therapies.
Global reach
workforce worldwide
pharmacomedical manufacturers
revenue
delivering to 160 countries
Meet our team
Global expertise
Wendy Hope Global Head of Regulatory Affairs
Read more >Eileen Carroll Quality Lead and Responsible Person
Read more >Maurice Leonard Medical Director | Uniphar Pharma
LinkedIn >Tom Smith Strategic Director, Advanced Therapies
Read more >Wayne McGarry Strategic Operations Director
Read more >Palvi Sharma Bains
Interim HR Director
LinkedIn >
Eileen has 14 years’ experience working in quality assurance across GDP, GMP and TE regulated environments. Since joining Uniphar in 2015, she has been responsible for the compliant management of unlicensed medicines across the Group’s businesses.
Wendy has over 15 years’ experience in pre-approval access, supporting 100+ programs across a variety of therapeutic areas.
Wendy is responsible for providing regulatory strategy and ensuring ongoing compliance throughout each program.
With over 14 years’ experience in life science, Damien is focused on the evolution of delivery models and service innovation within the Pre-Approval Access Unit. He is responsible for developing processes and operating structures that are suitable to deliver client programs.
Prior to joining in 2021, Damien worked in both pharmaceutical and medical device sales, marketing, and business development across specialist and primary care settings and multiple therapeutic areas.
Tom has seven years’ experience with expanded access programs, working with biotech and big pharma. During this time, he led the development of the EAP model to be suitable for gene therapies.
Tom’s role is focused on the delivery of strategic projects, collaborating with partners on their EAP strategy and Uniphar’s advanced therapy capabilities.
Dan has over 25 years pharmaceutical experience and worked in outsourced healthcare services for the majority of his time in industry.
Dan has held a variety of international leadership roles, working for UDG Healthcare, where he was General Manager for their US Commercial & Clinical operation. Dan was on the leadership team at AbbVie UK, where he led the launch of their Oncology franchise. Dan joined Uniphar in 2017 to lead their Product Access business, which specialises in the supply of unlicensed/pre-commercialisation medicine around the world.
A successful access program is, at its core, about collaboration. Partnering to provide patients with access to emerging and critical therapies, connecting all stakeholders in the access ecosystem. Working together we gather real-world data that assists product development and planning.